Regulation

Massachusetts Says Federal Cannabis Changes Leave State Rules Intact

Ava Morales
Add MyCannabis.com to your preferred sources on Google
Key PointsMassachusetts regulators say federal Schedule III changes do not alter state cannabis…
View more
  • Massachusetts regulators say federal Schedule III changes do not alter state cannabis enforcement or licensing obligations.
  • Only applicants who filed and paid between April 28 and June 26 2026 may operate while DEA registration stays pending.
  • Timely Applicants must verify trading partners and build compliant supply chains no later than November 29 2026.

The Massachusetts Cannabis Control Commission told marijuana establishments and medical marijuana treatment centers on November 18, 2026, that federal developments concerning Schedule III medical cannabis do not currently change its administration or enforcement of state cannabis laws. In a bulletin, Executive Director Travis Ahern shared DEA information explaining which registration applicants may continue operating and with whom they may trade while their federal applications remain pending.

The distinction matters for state-licensed businesses because the federal transition permits some medical-cannabis activity before DEA registration is granted, while Massachusetts requirements continue to apply. The Commission said federal cannabis-law administration and enforcement remain outside its jurisdiction, it has not received implementation guidance from federal agencies, and it cannot advise on DEA registration requirements or federal-law interpretation. It directed businesses and individuals to their own attorneys, tax professionals and other advisers for their specific circumstances.

The Commission will continue administering and enforcing Massachusetts cannabis laws and regulations, including G.L. c. 94G, G.L. c. 94I and 935 CMR 500.000 and 501.000. Licensees remain responsible for all applicable state requirements.

Eligibility Depends on Application Timing and State Licensure

The attached DEA document covers entities that submitted a completed application and paid the applicable registration fee between April 28, 2026, and June 26, 2026. The application must be for Schedule III medical marijuana registration under 21 CFR 1301.13(k), and the applicant must hold the requisite state medical marijuana license. Applicants that withdrew an application, received a final denial order or lack the required state license are excluded.

Qualifying dispenser, manufacturer and distributor applicants, collectively called Timely Applicants, may continue dispensing, manufacturing or distributing, as applicable, under their state medical marijuana licenses while their DEA applications are pending. This is an exception to the ordinary rule that regulated activity cannot begin until registration is granted and a certificate is issued. The covered products are Schedule III medical marijuana, marijuana extract and naturally derived delta-9-tetrahydrocannabinols as defined in federal regulations.

Trading Rules Require Supply-Chain Verification

Timely Applicants may conduct Schedule III medical marijuana activities with other Timely Applicants and with DEA registrants holding the appropriate registration. Timely Applicants and DEA registrants may not lawfully conduct those activities with entities outside those categories until the entities become DEA registrants. Unauthorized dealings could support denial of a Timely Applicant’s application or revocation of a registrant’s certificate.

The DEA’s listed due-diligence steps include obtaining the appropriate application or dispensary-information submission confirmation, verifying the applicant’s document control number through the DEA Diversion Control website, obtaining registrants’ certificates, checking that state licenses are active and retaining diligence records. Registrants must maintain Schedule III controlled-substance records under 21 CFR part 1304. For transactions with Timely Applicants, those records may use the applicant’s document control number where a DEA registration number would otherwise be required.

DEA expects Timely Applicants to verify existing trading partners, make necessary adjustments and establish compliant supply chains no later than November 29, 2026. Separately, Timely Dispenser Applicants and Timely Distributor Applicants may continue to possess, dispense and distribute existing Schedule III medical marijuana inventory acquired before the DEA information was issued. That includes inventory previously obtained from entities that qualify neither as Timely Applicants nor as DEA registrants.

Testing Discretion Has Narrow Conditions

For analytical testing, DEA said it does not intend to penalize registrants or Timely Applicants for sending de minimis quantities to a non-DEA-registered laboratory when registered laboratories are unavailable, provided the laboratory is in the same state as the applicant or registrant and detailed distribution records are retained. That discretion applies only when using a DEA-registered laboratory would violate state law: either no entities anywhere in the United States are registered for such testing, or state law prohibits out-of-state shipment and no laboratory in the applicant’s or registrant’s state is registered for it.

Analytical laboratories are not covered by the pending-applicant authority, and the document does not allow Timely Applicants or registrants to receive Schedule III medical marijuana from non-DEA-registered analytical laboratories. DEA states that the document does not have the force and effect of law and is intended to clarify existing legal requirements or Department of Justice policies, not bind the public.

Massachusetts oversight therefore remains intact as qualifying medical-cannabis operators move through a separate federal transition, one that makes verified trading partners, documented diligence and compliant supply chains central to their continued activity.

Ava Morales is an AI-generated research agent for MyCannabis.com, covering U.S. cannabis regulation with a focus on state-by-state legalization, medical programs, and consumer compliance. Her work helps readers navigate the fragmented legal landscape governing cannabis access, possession, and use across the United States.

With a structured and explanatory approach, Ava tracks legislative changes, ballot initiatives, and regulatory guidance affecting both medical and recreational cannabis markets. She emphasizes clarity over speculation, distinguishing clearly between enacted law, proposed reforms, and local enforcement realities so readers understand what is permitted in their jurisdiction today.

Articles authored by Ava Morales are AI-generated and reviewed by MyCannabis.com’s editorial team to ensure accuracy, neutrality, and responsible reporting on cannabis laws in regulated U.S. markets.